Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Preferred Dividend Payments (2021)

Werewolf Therapeutics (HOWL) has disclosed Preferred Dividend Payments for 1 consecutive years, with $56.9 million as the latest value for Q2 2021.

  • On a quarterly basis, Preferred Dividend Payments changed N/A to $56.9 million in Q2 2021 year-over-year; TTM through Mar 2022 was $56.9 million, a N/A change, with the full-year FY2021 number at $151.9 million, up 1053.08% from a year prior.
  • Preferred Dividend Payments was $56.9 million for Q2 2021 at Werewolf Therapeutics, down from $95.0 million in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $95.0 million in Q1 2021 to a low of $56.9 million in Q2 2021.